State of health economic evaluation research in Saudi Arabia: a review

Al-Aqeel, Sinaa

doi:10.2147/ceor.s31087

Cited by 31 publications

(22 citation statements)

References 23 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the reporting of price adjustments seems to be consistently poor, ranging from 18% to 41% in reviews of cost evaluation studies across pharmacology, complementary medicine, biomedical sciences, health care multi‐national trials and reproductive medicine, compared with 12% in our review. By contrast, the reporting of evaluation type, and the description of measurement and valuation processes appear to be more complete in these fields, ranging from 46% to 85% and 46% to 67%, respectively, compared with our findings of 29% and 40%, respectively. These differences may reflect a lower level of economic literacy in the HPE research field.…”

Section: Discussioncontrasting

confidence: 86%

“…Our finding of reporting deficiencies is similar to, if not slightly worse than, the findings of cost evaluation studies in other fields in the health and biomedical sciences . For example, the reporting of price adjustments seems to be consistently poor, ranging from 18% to 41% in reviews of cost evaluation studies across pharmacology, complementary medicine, biomedical sciences, health care multi‐national trials and reproductive medicine, compared with 12% in our review.…”

Section: Discussionsupporting

confidence: 78%

See 1 more Smart Citation

Cost evaluations in health professions education: a systematic review of methods and reporting quality

Foo

Cook

Walsh³

et al. 2019

Medical Education

View full text Add to dashboard Cite

Context High‐quality research into education costs can inform better decision making. Improvements to cost research can be guided by information about the research questions, methods and reporting of studies evaluating costs in health professions education (HPE). Our objective was to appraise the overall state of the field and evaluate temporal trends in the methods and reporting quality of cost evaluations in HPE research. Methods We searched the MEDLINE, CINAHL (Cumulative Index to Nursing and Allied Health Literature), EMBASE, Business Source Complete and ERIC (Education Resources Information Centre) databases on 31 July 2017. To evaluate trends over time, we sampled research reports at 5‐year intervals (2001, 2006, 2011 and 2016). All original research studies in HPE that reported a cost outcome were included. The Medical Education Research Study Quality Instrument (MERSQI) and the BMJ economic checklist were used to appraise methodological and reporting quality, respectively. Trends in quality over time were analysed. Results A total of 78 studies were included, of which 16 were published in 2001, 15 in 2006, 20 in 2011 and 27 in 2016. The region most commonly represented was the USA (n = 43). The profession most commonly referred to was that of the physician (n = 46). The mean ± standard deviation (SD) MERSQI score was 10.9 ± 2.6 out of 18, with no significant change over time (p = 0.55). The mean ± SD BMJ score was 13.5 ± 7.1 out of 35, with no significant change over time (p = 0.39). A total of 49 (63%) studies stated a cost‐related research question, 23 (29%) stated the type of cost evaluation used, and 31 (40%) described the method of estimating resource quantities and unit costs. A total of 16 studies compared two or more interventions and reported both cost and learning outcomes. Conclusions The absolute number of cost evaluations in HPE is increasing. However, there are shortcomings in the quality of methodology and reporting, and these are not improving over time.

show abstract

Section: Discussioncontrasting

confidence: 86%

Section: Discussionsupporting

confidence: 78%

Cost evaluations in health professions education: a systematic review of methods and reporting quality

Foo

Cook

Walsh³

et al. 2019

Medical Education

View full text Add to dashboard Cite

show abstract

“…The findings showed that the number of economic evaluation studies in Iran is limited. This is comparable with settings such as Bangladesh [60], Nigeria [26], Saudi Arabia [61], Zimbabwe [62], and lagging behind countries such as Thailand [29], South Korea [24], India [63] and South Africa [64]. The number of available studies remains very low compared with high-income countries where economic evaluation is a relatively well-established and formal part of the policy making process [21,65].…”

Section: Discussionsupporting

confidence: 74%

Do economic evaluation studies inform effective healthcare resource allocation in Iran? A critical review of the literature

Haghparast‐Bidgoli

Kiadaliri

Skordis‐Worrall

2014

Cost Eff Resour Alloc

View full text Add to dashboard Cite

To aid informed health sector decision-making, data from sufficient high quality economic evaluations must be available to policy makers. To date, no known study has analysed the quantity and quality of available Iranian economic evaluation studies. This study aimed to assess the quantity, quality and targeting of economic evaluation studies conducted in the Iranian context.The study systematically reviewed full economic evaluation studies (n = 30) published between 1999 and 2012 in international and local journals. The findings of the review indicate that although the literature on economic evaluation in Iran is growing, these evaluations were of poor quality and suffer from several major methodological flaws. Furthermore, the review reveals that economic evaluation studies have not addressed the major health problems in Iran.While the availability of evidence is no guarantee that it will be used to aid decision-making, the absence of evidence will certainly preclude its use. Considering the deficiencies in the data identified by this review, current economic evaluations cannot be a useful source of information for decision makers in Iran. To improve the quality and overall usefulness of economic evaluations we would recommend; 1) developing clear national guidelines for the conduct of economic evaluations, 2) highlighting priority areas where information from such studies would be most useful and 3) training researchers and policy makers in the calculation and use of economic evaluation data.

show abstract

“…On average, scores were suboptimal and this was mainly due to the numerous methodological shortcomings and poorly justified modelling assumptions. Suboptimal quality of economic evaluations was also reported by previous systematic reviews …”

Section: Discussionmentioning

confidence: 69%

“…Suboptimal quality of economic evaluations was also reported by previous systematic reviews. 45,50,51…”

Section: Discussionmentioning

confidence: 99%

Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review

et al. 2016

View full text Add to dashboard Cite

This is an interesting systematic review of studies specifically addressing the economic evaluation of interventions to lower phosphate in dialysis patients. Only 12 studies provided information, all relating to phosphate binders. In general, the overall quality of these studies was suboptimal; therefore, firm conclusions were difficult to be drawn about which binders were best, although calcium-based binders seemed most cost-effective as first-line therapy. ABSTRACT:Managing hyperphosphataemia in haemodialysis patients is resourceintensive. A search for cost-effective interventions in this field is needed to inform decisions on the allocation of healthcare resources. NHSEED, MEDLINE, EMBASE and CINAHL were searched for full economic evaluations of hyperphosphataemia-managing interventions in adult haemodialysis patients, published between 2004 and 2014, in English, French, Dutch or German. Incremental cost-effectiveness ratios of the interventions were up-rated to 2013US$ using Purchasing Power Parity conversion rates and Consumer Price Indices. The quality of included studies was assessed using the Extended Consensus on Health Economic Criteria List. Twelve out of the 1681 retrieved records fulfilled the inclusion criteria. They reported only on one aspect of hyperphosphataemia management, which is the use of phosphate binders (calcium-based and calcium-free, in first-line and sequential use). No economic evaluations of other phosphorus-lowering interventions were found. The included articles derived from five countries and most of them were funded by pharmaceutical companies. The incremental costeffectiveness ratios of phosphate binders ranged between US$11 461 and US$157 760 per quality-adjusted life-year gained. Calcium-based binders (especially calcium acetate) appear to be the optimal cost-effective first-and second-line therapy in prevalent patients, while the calcium-free binder, lanthanum carbonate, might provide good value for money, as second-line therapy, in incident patients. The studies' overall quality was suboptimal. Drawing firm conclusions was not possible due to the quality heterogeneity and inconsistent results. Future high-quality economic evaluations are needed to confirm the findings of this review and to address other interventions to manage hyperphosphataemia in this population.

show abstract

State of health economic evaluation research in Saudi Arabia: a review

Cited by 31 publications

References 23 publications

Cost evaluations in health professions education: a systematic review of methods and reporting quality

Cost evaluations in health professions education: a systematic review of methods and reporting quality

Do economic evaluation studies inform effective healthcare resource allocation in Iran? A critical review of the literature

Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review

Contact Info

Product

Resources

About